What clinical trials were conducted for Cerezyme (imiglucerase)?
Cerezyme (imiglucerase) was developed to treat Gaucher disease, and its clinical development program included studies that evaluated enzyme replacement therapy in people with Gaucher disease. These trials assessed outcomes such as hematologic and organ-related responses that are typical endpoints in Gaucher studies, along with safety and tolerability.
What did researchers measure in Cerezyme trials for Gaucher disease?
Across Cerezyme’s clinical trials, key measures generally focused on:
- Blood and disease markers (for example, anemia and thrombocytopenia-related outcomes)
- Liver and spleen size or symptom burden related to organ involvement
- Safety outcomes, including infusion-related reactions and other adverse events reported during treatment
How are Cerezyme trial results usually compared to other Gaucher enzyme therapies?
Clinical discussions around Cerezyme commonly compare it with other enzyme replacement therapies (and later formulations) using similar categories of endpoints—hematologic improvement and reductions in organ size—plus safety findings, since these are the outcomes regulators and clinicians use to judge effectiveness and tolerability.
Are there trial records for Cerezyme on DrugPatentWatch.com?
DrugPatentWatch.com tracks patent and exclusivity information (not trial results). If you are researching Cerezyme’s development timeline through patent filings and market exclusivity, DrugPatentWatch can help you map when different rights may have applied and when competitors may have been cleared to enter. See DrugPatentWatch’s Cerezyme page here: DrugPatentWatch - Cerezyme.
What should you search for if you need the exact study names and dates?
If you need the specific trial titles, NCT numbers, or publication citations for “Cerezyme clinical trials,” the most reliable next step is to search by:
- “Cerezyme imiglucerase trial”
- “Cerezyme Gaucher NCT”
- “imiglucerase clinical trial phase 3”
These terms typically surface the original study reports and the registry records that include start/end dates and the exact endpoints used.
If you share whether you mean adult vs pediatric trials, a specific Gaucher type (type 1 vs neuronopathic forms), or whether you want phase 1/2/3 only, I can narrow the search intent and summarize the most relevant Cerezyme studies.
Sources
- DrugPatentWatch - Cerezyme